Image Source: Pixabay

Tsumura & Co Ltd (TSMRF) is a specialty and generic drug manufacturing company.

The company generates most of its revenue through prescription Kampo products, followed by over-the-counter medicines.

Tsumura promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers.

The company considers strategic collaboration agreements to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Tsumura & Co. was founded in 1893 and is headquartered in Tokyo, Japan.

Three key data points gauge Tsumura & Co. or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three keys also best tell whether any company has made, is making, and will make money.

TSMRF Price

Share price increased 35.7% in the past year from $18.10 to $28.15, as of Wednesday’s market close.

In the past 3 years, the company’s share price has ranged from $18.10 to $28.15. (Its all-time high of $34.68 was reached June 11, 2021.

The company may repeat its average annual past performance and its price could grow by $3.35 next year.

TSMRF Dividend

Tsumura & Co has paid variable semi-annual dividends since December 5, 2011. The company’s most recent SA dividend of $0.45 was declared May 9th for shareholders of record prior to March  28, 2025, and the payout is likely due June 30th. A forward-looking annual dividend of $0.91 yields 3.22% per Wednesday’s closing price.

TSMRF Returns

Putting it all together, an $4.26 estimated gross gain per share shows up by adding TSMRF’s annual $0.91 dividend to the estimated $3.35 annual price gain, totaling that $4.26 gross amount.

A little over $1000 buys 36 shares at Tuesday’s $28.15 share price.

A $10 broker fee (if charged), collected half at purchase and half at sale, might take about $0.28 per share out of the $4.26 gross gain to give us a net gain of $3.98 X 36 shares = $143.28 for about a 14.3% estimated net gain on the year.

Furthermore, the $32.20 annual dividend income from $1k invested in TSMRF is nearly $4.00 more than the single-share price. By these numbers, TSMRF may be an ideal dividend dog.

Therefore, you may choose to pounce on Tsumura & Co. as a 132-year-old semi-annual dividend-paying pharmaceutic; company with a 14-year dividend record.

The exact track of Tsumura & Co future price and dividend will entirely be determined by market action and company finances.

Remember the best way to track stock performance and dividend payments is through direct ownership of company shares.

More By This Author:

Current Report: Sundrug Co Ltd
Current Report: Patterson Companies
Current Report Extendicare Inc (EXETF)